ARTICLE | Clinical News
Velcade bortezomib: Phase II data; approved in U.S
June 30, 2003 7:00 AM UTC
Previous reported results from the open-label Phase II SUMMIT trial showed 67 of 193 (35%) evaluable patients had a complete, partial or minimal response to Velcade alone. Included in the 67 patients ...